

 Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch	Section <i>Pharmacy Professional Services</i>	Reference DP-PPS-16
		Date of Issue November 1, 2018
		Revised May 1, 2026
INJECTION ADMINISTRATION PROGRAM POLICY and PROCEDURES		

POLICY

- Effective November 1, 2018, the Drug Plan and Extended Benefits Branch (DPEBB) will pay an Injection Administration Fee (IAF) to pharmacies according to Table 1 (Injection Administration Program (IAP) Billing Code and Billing Threshold/Limitations) when the medication in Appendix I is administered:
- By a certified licensed pharmacist according to the *Regulatory Bylaws of the Saskatchewan College of Pharmacy Professionals (SCPP)* who maintains a current Advanced Method Certification;
- To an eligible patient; and
- By injection;
- The IAF amount is listed in Schedule B of the current Pharmacy Proprietor Agreement. DPEBB pays 100% of the IAF for eligible patients.
- The IAF payment remunerates the pharmacy for all activities/expenses related to provision of the service (e.g., patient assessment, supplies, administration of the medication, monitoring the patient, drugs and supplies used to manage adverse events following administration and required record-keeping).
- **No incentives shall be provided** by the Proprietor or an agent on behalf of the Proprietor to any other person in relation to the provision of IAF.
“incentives” means any money, gifts, donations to a charity, rebates, refunds, customer loyalty programs, points, coupons, discounts, goods, dividends and/or rewards which can be redeemed for a gift or other benefit.

PURPOSE

- To increase access for Saskatchewan residents to services requiring injection of designated prescribed medications.

LEGISLATIVE AUTHORITY

- *The Health Administration Act, (Saskatchewan)*
- *The Pharmacy and Pharmacy Disciplines Act, 2015*
- *The Prescription Drugs Act (Saskatchewan)*

ELIGIBILITY

- An eligible patient under the IAP is a resident of Saskatchewan with a valid Saskatchewan Health Services Number, and is in accordance with the clinical indication and age limits as defined in the product monograph.
- *Exclusions: Residents of a Special-care Home are not eligible for an IAF
A Special-care Home, formerly referred to as a Long-term Care Facility, is defined as a designated facility that provides personal or nursing care to individuals who reside in the home on a temporary or permanent basis. The home may provide any of the following types of care: convalescent care; rehabilitation services; palliative care; respite care; and day programming. Special-care homes are operated by the Saskatchewan Health Authority or by a provider that has a contract with the Saskatchewan Health Authority.

PROCEDURES

The Pharmacist will:

- Adhere to the *Regulatory Bylaws of the Saskatchewan College of Pharmacy Professionals*
- Confirm patient eligibility.
- Document the patient interaction using the SCPP record-keeping requirements.
- Pharmacists must follow the requirements for obtaining and documenting consent according to the SCPP's *Policies, Standards and Guidelines for Pharmacists in the Administration of Drugs by Injection and Other Routes* at <https://saskpharm.ca/site/profprac/adminofdrugs?nav=sidebar>.
- Ensure the product is administered as per the product monograph.
- Ensure the product record is successfully transmitted to the Pharmaceutical Information Program (PIP).
- Pharmacists must follow the requirements of the SCPP regarding the reporting of adverse events. The reporting form is available at <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>

The Pharmacy will:

- Submit the record of the injection medication dispensed electronically for adjudication or capture to DPEBB according to usual DPEBB drug claims submission processes. This must be submitted before submitting the IAF claim.
- The medication does not need to be dispensed at the same pharmacy that is administering the injection. However, the pharmacy must confirm that the medication was stored as per the product monograph.
- Submit the claim for the IAF electronically to DPEBB on the date of the injection service using the appropriate pseudoDIN listed in Table 1.
- Paper claims will not be accepted for the IAF.
- Retain all relevant documentation as per the SCPP Reference Manual - [Record Retention and Destruction](#) guidelines
- Upon DPEBB's request, provide copies of the administration record within two (2) business days as part of DPEBB's review of pharmacist and pharmacies adherence to the IAP Policy and Procedures.

The Drug Plan and Extended Benefits Branch will:

- Remunerate pharmacies the IAF upon receipt of the electronic claim.
- Establish additional record-keeping requirements for the IAP as required.
- Request and review all documentation to confirm pharmacists and pharmacies have adhered to the IAP Policy and Procedures. All forms may be requested.
- Recover the IAF if the DPEBB determines, based on its review, there was non-compliance with the IAP policy and procedures.

BILLING PROCEDURE:

- Dispense the injection medication and electronically submit the record for adjudication or capture to the DPEBB on the date of the dispense using the product DIN in Appendix I (Step 1: Record of the Injection Product Dispensed and Administered). The medication does not have to be dispensed at the same pharmacy that is administering the injection.
- Submit the claim for the IAF electronically to the DPEBB on the date of administration of the medication using the pseudoDIN in Table 1 (Step 2: Injection Administration Fee).

STEP 1: Record of the Injection Product Dispensed and Administered

- The record of the injection medication product dispensed must be **submitted** according to current DPEBB submission requirements.
- The record of the injection medication product administered must be submitted before the IAF.
- Ensure the following fields are completed as follows:
 - **PATIENT IDENTIFIER** = nine-digit Health Services Number (HSN)
 - **DISPENSING DATE** = date of the medication dispense(e.g., November 1, 2018)
 - **RX NUMBER** = enter the sequential RX#
 - **HEALTH PROVIDER ORGANIZATION ID** = SKCP, SK, SKMS
 - **HEALTH PROVIDER ID** = Pharmacist ID number (e.g., D1234), or Physician 10-digit Health Provider ID (e.g., 0000007890)
 - **PHARMACIST ORGANIZATION ID** = SK
 - **PHARMACIST ID** = Pharmacist ID number (e.g., D1234)
 - **DIN** = enter the DIN of the product prescribed and/or dispensed (refer to Appendix I)
 - **COMPOUNDING FEE (CF)** = \$0.00
 - **COMPOUND NAME** = blank
 - **QUANTITY (QTY)** = enter quantity dispensed
 - **DAYS SUPPLY** = enter days supply dispensed
 - **ACQUISITION COST (AC)** = enter actual acquisition cost
 - **DISPENSING FEE (DF)** = enter usual and customary fee
 - **MARKUP** = tiered as per Pharmacy Proprietor Agreement
 - **TOTAL RX COST** = enter total cost
 - **PATIENT PAID** = as appropriate
 - **ADJUDICATION FLAG** = Y/N

- Please note: If the medication is prescribed by a pharmacist, the pharmacy can also submit a claim for the appropriate prescriptive authority fee.

Step 2: Injection Administration Fee (IAF)

- The DPEBB pays 100% of the IAF to the pharmacy.
- Ensure the following fields are completed as follows:
 - **PATIENT IDENTIFIER** = nine-digit Health Services Number (HSN)
 - **DISPENSING DATE** = date of the IAF (e.g., November 1, 2018)
 - **RX NUMBER** = enter the sequential RX#
 - **HEALTH PROVIDER ORGANIZATION ID** = SKCP
 - **HEALTH PROVIDER ID** = Pharmacist ID number (e.g., D1234)
 - **PHARMACIST ORGANIZATION ID** = SK
 - **PHARMACIST ID** = Pharmacist ID number (e.g., D1234)
 - **DIN** = pseudoDIN as per Table 1
 - **COMPOUNDING FEE (CF)** = \$0.00
 - **COMPOUND NAME** = blank
 - **QUANTITY (QTY)** = 1 (refer to limitations according to Table 1)
 - **DAYS SUPPLY** = 1
 - **ACQUISITION COST (AC)** = \$18.00
 - **DISPENSING FEE (DF)** = \$0.00
 - **MARKUP** = 00 / 00 / 00
 - **TOTAL RX COST** = \$18.00
 - **PATIENT PAID** = \$0.00
 - **ADJUDICATION FLAG** = Y

- Please note: DPEBB will not accept paper claims for the IAF.
- Your Practice Management System should work with the billing code (pseudoDIN).
- If you are unable to submit either the record of the injection product or the IAF electronically through your Practice Management System, use the secure DPEBB **WEB page** by logging on to <https://www.drugplan.health.gov.sk.ca>.
- If you are not sure how to install the WEB certificate, contact your software vendor. To use the secure DPEBB **WEB page**, refer to the DPEBB Pharmacy Reference Manual, Section VI.

Table 1: Injection Administration Program Billing Code (Fee/Limitations)

Billing Code (pseudoDIN)	Injection Product	Billing Threshold/Limitation
00951373	Medroxyprogesterone acetate injectable suspension	Billing limits are based on product monographs.
00951388	Long-acting antipsychotics (single use)	Pharmacies may submit claims up to 14 days after the product record submission.
00951386	Buprenorphine Injection (i.e., Sublocade™)	Must be submitted as a Quantity of ONE (1).
00951387	Testosterone	Billing limits are based on product monographs.
00951389	Long-acting antipsychotics (multi- dose vials)	Must be submitted as a Quantity of ONE (1).

Appendix I:
Eligible Product Information for Saskatchewan Pharmacies

PSEUDODIN	INJECTION	ELIGIBLE INJECTION PRODUCT- GENERIC NAMES	DIN	Brand Name	Strength
00951373	MEDROXYPROGESTERONE ACETATE INJECTION	MEDROXY-PROGESTERONE ACETATE	02523493	DEPO PROVERA	150MG/ML PFS
00951386	BUPRENORPHINE INJECTION	BUPRENORPHINE	02483084	SUBLOCADE (EDS)	100MG/0.5ML ER SUBCUTANEOUS SOLUTION
		BUPRENORPHINE	02483092	SUBLOCADE (EDS)	300MG/1.5ML ER SUBCUTANEOUS SOLUTION
00951388	LONG ACTING ANTI-PSYCHOTICS SINGLE USE VIALS/SYRINGES	FLUPENTIXOL DECANOATE	02156032	FLUANXOL DEPOT	20MG/ML INJECTION SOLUTION (ML)
		FLUPENTIXOL DECANOATE	02156040	FLUANXOL DEPOT	100MG/ML INJECTION SOLUTION (ML)
		ZUCLOPENTHIXOL DECANOATE	02230406	CLOPIXOL DEPOT	200MG/ML INJECTION (ML)
		RISPERIDONE	02255707	RISPERDAL CONSTA (EDS)	25MG/VIAL POWDER FOR INJECTION (VIAL)
		RISPERIDONE	02255723	RISPERDAL CONSTA (EDS)	37.5MG/VIAL POWDER FOR INJECTION (VIAL)
		RISPERIDONE	02255758	RISPERDAL CONSTA (EDS)	50MG/VIAL POWDER FOR INJECTION (VIAL)
		RISPERIDONE	02298465	RISPERDAL CONSTA (EDS)	12.5MG/VIAL POWDER FOR INJECTION (VIAL)
		RISPERIDONE	02544601	OKEDI*	75MG PFS
		RISPERIDONE	02544628	OKEDI*	100MG PFS
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02354217	INVEGA SUSTENNA (EDS)	50MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02354225	INVEGA SUSTENNA (EDS)	75MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02354233	INVEGA SUSTENNA (EDS)	100MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02354241	INVEGA SUSTENNA (EDS)	150MG INTRAMUSCULAR SUSPENSION

PSEUDODIN	INJECTION	ELIGIBLE INJECTION PRODUCT- GENERIC NAMES	DIN	Brand Name	Strength
		ARIPIRAZOLE	02420864	ABILIFY MAINTENA (EDS)	300MG/VIAL LONG ACTING INJECTION
		ARIPIRAZOLE	02420872	ABILIFY MAINTENA (EDS)	400MG/VIAL LONG ACTING INJECTION
		ARIPIRAZOLE	02554569	ABILIFY ASMITUFII*	720MG PFS
		ARIPIRAZOLE	02554577	ABILIFY ASMITUFII*	960MG PFS
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02455943	INVEGA TRINZA (EDS)	175MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02455986	INVEGA TRINZA (EDS)	263MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02455994	INVEGA TRINZA (EDS)	350MG INTRAMUSCULAR SUSPENSION
		PALIPERIDONE (PALIPERIDONE PALMITATE)	02456001	INVEGA TRINZA (EDS)	525MG INTRAMUSCULAR SUSPENSION
00951389	LONG ACTING ANTI- PSYCHOTICS MULT- DOSE VIALS	HALOPERIDOL DECANOATE	02130300	HALOPERIDOL LA	100MG/ML INJECTION SOLUTION (5ML)
00951387	TESTOSTERONE	TESTOSTERONE CYPIONATE	02496003	TARO- TESTOSTERON E CYPION	100MG/ML OILY INJECTION SOLUTION (10ML)
		TESTOSTERONE ENANTHATE	02536315	TESTOSTERON E ENANTHATE	200MG/ML OILY INJECTION SOLUTION (5ML)

*non-formulary drugs